top of page

Our unique technology enables the design of ADCs with improved efficacy and better tolerability while unlocking the use of novel payloads

Next-generation antibody-drug conjugates
powered by the exclusive ​PSARLink™ platform 

our lead ADC candidate

  • Validated druggable target: FR⍺
  • Potential to address:
    • Ovarian Cancer,
    • Triple Negative Breast Cancer,
    • Non-Small Cell Lung Cancer,
    • Colorectal Cancer
  • Exatecan (anti topo-I) as payload
  • Excellent pharmacological profile thanks to PSARLink™ 
Clinical trials planned to start in 2024 based on promising preclinical results.

News Archive

bottom of page